FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a method of treating pancreatic cancer in a patient, comprising administering to a patient in need thereof, an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, where R1 is a halogen; R2 is C1-6 haloalkyl; R3 is hydrogen or C1-6 alkyl; R4 is hydrogen; n is 0 and A1 is -CH- or -N-, A2 is -CH- and A3 is -N-. Invention also relates to a pharmaceutical combination for treating pancreatic cancer, comprising a compound of Formula I and one or more additional therapeutic compounds selected from FOLFIRINOX or gemcitabine and paclitaxel.
.
EFFECT: effective method of treating pancreatic cancer based on the compound of Formula I.
11 cl, 2 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
COMBINATIONS (COMPOSITIONS), INCLUDING DMXAA FOR CANCER TREATMENT | 2006 |
|
RU2404765C2 |
METHOD FOR TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS | 2017 |
|
RU2765737C2 |
SOLUBLE C5aR ANTAGONISTS | 2017 |
|
RU2748260C2 |
PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
MODULATORS CCR2 | 2016 |
|
RU2726206C2 |
METHOD FOR RECEPTOR TYROSINE KINASE INHIBITION WITH USE EXTRACELLULAR ANTAGONIST AND INTRACELLULAR ANTAGONIST | 2004 |
|
RU2431500C2 |
METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
BIOMARKERS AND APPLICATIONS IN TREATING VIRAL INFECTIONS, INFLAMMATIONS OR CANCER | 2019 |
|
RU2820481C2 |
TREATING CANCER WITH COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2704811C2 |
Authors
Dates
2022-03-24—Published
2017-06-13—Filed